May 28, 2026 07:00AM
Apr 20, 2026 05:00PM
Apr 20, 2026 05:00PM
Apr 19, 2026 10:00AM
Mar 30, 2026 07:01AM
Mar 30, 2026 07:00AM
Feb 18, 2026 07:00AM KalVista's EKTERLY recommended as first-line therapy in pediatric HAE guideline
Feb 18, 2026 07:00AM
Jan 7, 2026 06:30PM
Sep 11, 2025 07:02AM
Sep 11, 2025 07:00AM
Jul 25, 2025 08:00AM
Jul 25, 2025 08:00AM
Jul 15, 2025 04:05PM KalVista wins UK approval for oral hereditary angioedema treatment
Jul 15, 2025 04:05PM
Jul 11, 2025 06:37AM
Jul 10, 2025 10:29AM
Jul 10, 2025 07:00AM
Jul 7, 2025 02:40PM
Jul 7, 2025 06:31AM
Jul 7, 2025 06:30AM KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
Jul 2, 2025 04:05PM
Jun 26, 2025 07:02AM
Jun 26, 2025 07:00AM
Jun 24, 2025 03:50PM
Jun 24, 2025 01:57PM
Jun 16, 2025 07:28AM
Jun 16, 2025 07:03AM KalVista Pharmaceuticals (KALV) Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat
Jun 16, 2025 07:00AM
Jun 16, 2025 04:19AM
Jun 13, 2025 04:06PM
Jun 13, 2025 04:05PM
Jun 5, 2025 07:00AM
Jun 3, 2025 04:01PM
Jun 2, 2025 07:00AM KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
May 29, 2025 07:00AM
May 22, 2025 07:00AM
May 2, 2025 07:00AM
Apr 30, 2025 07:00AM
Apr 8, 2025 06:31AM
Apr 8, 2025 06:30AM
Apr 2, 2025 07:00AM KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 31, 2025 07:00AM
Mar 25, 2025 07:02AM
Mar 25, 2025 07:00AM
Mar 12, 2025 07:00AM
Mar 10, 2025 07:00AM
Mar 4, 2025 07:00AM
Mar 3, 2025 07:05AM KalVista Pharmaceuticals (KALV) Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
Mar 3, 2025 07:00AM

322,215 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All